Cellix Bio

About Cellix Bio

Cellix Bio is a biopharmaceutical company founded in 2014 by Mahesh Kandula, who serves as the Managing Director and CEO. Headquartered in Hyderabad, India, the firm focuses on designing and developing therapies for neurological, inflammatory, and metabolic diseases. The company's core is its proprietary Synergix AI™ technology platform, which accelerates the drug discovery process. This platform designs novel molecular entities with synergistic pharmacological properties, creating medicines that modulate multiple targets in a disease pathway to enhance efficacy and reduce risk.

Mahesh Kandula is an entrepreneur with over 18 years of experience in life sciences and is the inventor of the Synergix platform. He holds a Master of Technology degree from IIT Kharagpur and has been named as an inventor on over 160 international patents and more than 72 in the U.S. His work focuses on developing new molecular entities across a wide range of therapeutic areas, including oncology, diabetes, and neurodegenerative diseases. The company's board includes co-founder Subbu Apparsundaram, Achanna Chowdary Valluri, and others.

Cellix Bio operates on a business model centered around creating value through its intellectual property by developing a robust pipeline of new medicines that address unmet medical needs. The company collaborates with scientific communities, universities, and research institutions to advance its technology and pipeline. It generates revenue through collaborations and licensing transactions with other biopharmaceutical companies. For example, Cellix Bio has engaged in licensing deals and received investment from firms like V ClinBio, which acquired a significant equity stake in 2018 to advance the Synergix platform. The company has raised a total of $4.64 million in funding. In 2020, its subsidiary, Cellix Bio Pharma, a contract research organization (CRO), acquired Avaca Pharma to bolster its pharmaceutical development capabilities.

The company's product pipeline includes drug candidates like CLX-106 for relapsing-remitting multiple sclerosis and CLX-103 for ulcerative colitis, both developed using the Synergix platform. By using the 505(b)(2) regulatory pathway for some of its drugs, Cellix Bio aims for a more cost-effective and faster path to approval.